Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report.
Gynecol Oncol Rep 2021;
37:100817. [PMID:
34258357 PMCID:
PMC8253948 DOI:
10.1016/j.gore.2021.100817]
[Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Revised: 06/18/2021] [Accepted: 06/20/2021] [Indexed: 12/13/2022] Open
Abstract
•Checkpoint inhibitor therapy affecting PD-L1 as treatment for advanced solid tumors.•Success in trial pembrolizumab therapy in multiresistant metastatic choriocarcinoma.•Long-term remission after pembrolizumab therapy in multiresistant choriocarcinoma.•Only six reported cases, one with comparable follow-up and outcome.
Collapse